Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects

Glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged as treatment options for type 2 diabetes mellitus (T2DM). Here, we designed a high-throughput GLP-1R extracellular domain (ECD)-based system that enabled the screening of high-potency receptor-biased GLP-1R agonists demonstrating new ph...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Xia, Chen, Zhu, Chen, Qiong, Zhao, Wei, Chen, Zhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412877/
https://www.ncbi.nlm.nih.gov/pubmed/30795583
http://dx.doi.org/10.3390/molecules24040779

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412877/
https://www.ncbi.nlm.nih.gov/pubmed/30795583
http://dx.doi.org/10.3390/molecules24040779

Ejemplares similares